Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation

Journal of Hypertension

Volumn 26, Issue 8, 2008, Pages 1629-1635

  Yang, Xiaoli ^a,b   Wang, Feng ^a   Chang, Hailiang ^c   Zhang, Suli ^a   Yang, Lihong ^a   Wang, Xiaoliang ^a   Cheng, Xiaolong ^a   Zhang, Mingsheng ^c   Ma, Xin L ^d   Liu, Huirong ^a,c,e  

^a Department of Physiology ^*  (China)

^b Laboratory of Cellular Physiology   (China)

^c SHANXI MEDICAL UNIVERSITY   (China)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin II; Autoantibody; Preeclampsia; Pregnancy; Vascular ring

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; IMMUNOGLOBULIN G; LOSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; AUTOANTIBODY;

ADULT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BRAIN ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NONHUMAN; PREECLAMPSIA; PRIORITY JOURNAL; RAT; THORACIC AORTA; VASOCONSTRICTION; ANIMAL; BLOOD; DOSE RESPONSE; DRUG EFFECT; HYPERTENSION; IMMUNOLOGY; IN VITRO STUDY; METABOLISM; PREGNANCY; RISK FACTOR; WISTAR RAT;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA, THORACIC; AUTOANTIBODIES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; HYPERTENSION; IMMUNOGLOBULIN G; LOSARTAN; MALE; PRE-ECLAMPSIA; PREGNANCY; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RISK FACTORS; VASOCONSTRICTION;

EID: 51549083504     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328304dbff     Document Type: Article

References (23)

1. Boulanger H, Flamant M. New insights in the pathophysiology of preeclampsia and potential therapeutic implications. Nephrol Ther 2007; 3:437-448.
2. Stepan H, Heihoff-Klose A, Faber R. Reduced antioxidant capacity in second-trimester pregnancies with pathological uterine perfusion. Ultrasound Obstet Gynecol 2004; 23:579-583.
3. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin ATI receptor. J Clin Invest 1999; 103:945-952.
4. 2+ mobilization through angiotensin receptor activation. Circulation 2004; 110:1612-1619.
5. Dechend R, Viedt C, Muller DN, Ugele B, Brandes RP, Wallukat G, et al. AT1. receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 2003; 107:1632-1639.
6. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20:IX-IXV.
7. Liu HR, Zhao RR, Zhi JM, Wu BW, Fu ML. Screening of serum autoantibodies to cardiac beta1-adrenoceptors and M2-muscarinic acetylcholine receptors in 408. healthy subjects of varying ages. Autoimmunity 1999; 29:43-51.
8. Kezic A, Sparić R, Stojimirović B, Milenković V. Multiorgan dysfunction in a gravid woman with placental abruption and disseminated intravascular coagulation. Srp Arh Celok Lek 2007; 135:465-467.
9. Weinberger MH, Kramer NJ, Petersen LP, Cleary RE, Young PC. Sequential changes in the renin-angiotensin -aldosterone systems and plasma progesterone concentration in normal and abnormal human pregnancy. Perspect Nephrol Hypertens 1976; 5:263-269.
10. Cooper AC, Robinson G, Vinson GP, Cheung WT, Broughton PF. The localization and expression of the renin -angiotensin system in the human placenta throughout pregnancy. Placenta 1999; 20:467-474.
11. Gant NF, Daley GL, Chand S, Whalley PJ, MacDonald PC. A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest 1973; 52:2682-2689.
12. Kyle PM, Buckley D, Kissane J, de Swiet M, Redman CW. The angiotensin sensitivity test and low-dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. Am J Obstet Gynecol 1995; 173:865-872.
13. Davison JM, Homuth V, Jeyabalan A, Conrad KP, Karumanchi SA, Quaggin S, et al. New aspects in the pathophysiology of preeclampsia. J Am Soc Nephrol 2004; 15:2440-2448.
14. Dechend R, Homuth V, Wallukat G, Kreuzer J, Park JK, Theuer J, et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 2000; 101:2382-2387.
15. Dechend R, Homuth V, Wallukat G, Muller DN, Krause M, Dudenhausen J, et al. Agonistic antibodies directed at the angiotensin II. AT1. receptor in preeclampsia. J Soc Gynecol Investig 2006; 13:79-86.
16. Xia Y, Wen H, Bobst S, Day MC, Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Investig 2003; 10:82-93.
17. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 1998; 179:1359-1375.
18. Bobst SM, Day MC, Gilstrap LC III, Xia Y, Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6. and plasminogen activator inhibitor-1. secretion. Am J Hypertens 2005; 18:330-336.
19. Luther HP, Homuth V, Wallukat G. Alpha 1-adrenergic receptor antibodies in patients with primary hypertension. Hypertension 1997; 29:678-682.
20. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe preeclamptic pregnancies. Br J Obstet Gynaecol 1994;101:669-674.
21. Barden A. Preeclampsia: contribution ofmaternal constitutional factors and the consequences for cardiovascular health. Clin Exp Pharmacol Physiol 2006; 33:826-830.
22. Funai EF, Friedlander Y, Paltiel O, Tiram E, Xue X, Deutsch L, Harlap S. Long-term mortality after preeclampsia. Epidemiology 2005; 16:206-215.
23. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after preeclampsia: population based cohortstudy. BMJ 2001;323:1213-1217.